Trial Profile
Phase II Trial of Nab-paclitaxel (Abraxane) in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 16 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 20 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
- 03 Jun 2016 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2016.